Judicial structural modifications of 5:7-fused ring-expanded nucleosides (RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic heterocycle (1). The latter exhibited promising broad-spectrum in vitro anti-cancer activity against a number of cancer cell lines screened. This paper describes our systematic, albeit limited, structure-activity relationship (SAR) studies on this lead compound, which produced a number of analogs with broad-spectrum in vitro anti-cancer activities against lung, breast, prostate, and ovarian cancer cell lines, in particular compounds 15i, 15j, 15m and 15n which showed IC(50) values in submicromolar to micromolar range, and are worthy of further explorations. The SAR data also enabled us to propose a tentative SAR model for future SAR efforts for ultimate realization of optimally active and minimally toxic anti-cancer compounds based on the diimidazo[4,5-d:4',5'-f][1,3]diazepine structural skeleton of the lead compound 1.
Judicial structural modifications of 5:7-fused ring-expanded class="Chemical">nucleosides (class="Chemical">n class="Chemical">RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic heterocycle (1). The latter exhibited promising broad-spectrum in vitro anti-cancer activity against a number of cancer cell lines screened. This paper describes our systematic, albeit limited, structure-activity relationship (SAR) studies on this lead compound, which produced a number of analogs with broad-spectrum in vitro anti-cancer activities against lung, breast, prostate, and ovarian cancer cell lines, in particular compounds 15i, 15j, 15m and 15n which showed IC(50) values in submicromolar to micromolar range, and are worthy of further explorations. The SAR data also enabled us to propose a tentative SAR model for future SAR efforts for ultimate realization of optimally active and minimally toxic anti-cancer compounds based on the diimidazo[4,5-d:4',5'-f][1,3]diazepine structural skeleton of the lead compound 1.
Authors: Ramesh K Sood; Vishweshwar S Bhadti; Ali I Fattom; Robert B Naso; Brent E Korba; Earl R Kern; Huan-Ming Chen; Ramachandra S Hosmane Journal: Antiviral Res Date: 2002-02 Impact factor: 5.970
Authors: Atul Kondaskar; Shilpi Kondaskar; Raj Kumar; James C Fishbein; Nidal Muvarak; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Guus M Bol; Farhad Vesuna; Venu Raman; Ramachandra S Hosmane Journal: ACS Med Chem Lett Date: 2010-12-31 Impact factor: 4.345
Authors: Ning Zhang; Huan-Ming Chen; Verena Koch; Herbert Schmitz; Ching-Len Liao; Maria Bretner; Vishweshwar S Bhadti; Ali I Fattom; Robert B Naso; Ramachandra S Hosmane; Peter Borowski Journal: J Med Chem Date: 2003-09-11 Impact factor: 7.446
Authors: Min Xie; Farhad Vesuna; Saritha Tantravedi; Guus M Bol; Marise R Heerma van Voss; Katriana Nugent; Reem Malek; Kathleen Gabrielson; Paul J van Diest; Phuoc T Tran; Venu Raman Journal: Cancer Res Date: 2016-09-12 Impact factor: 12.701